2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.117 Apar Ganti NACLC23 Abstract

PP01.117 Apar Ganti NACLC23 Abstract

Pdf Summary

This study evaluated the real-world effectiveness and safety of lurbinectedin and other second-line treatments in patients with small cell lung cancer (SCLC). Lurbinectedin monotherapy (LM) is approved for metastatic SCLC patients who have progressed on platinum-based chemotherapy. The study used a retrospective cohort analysis of patients in the Flatiron Health database from January 2013 to April 2022.<br /><br />In total, 552 patients were included in the analysis, with 291 patients receiving LM and 261 receiving other second-line treatments (OST). After propensity score matching, baseline characteristics were balanced between the two groups. The study found that real-world effectiveness was similar between LM and OST, but a suggestion of better outcomes was observed with LM in platinum-sensitive patients. In the chemotherapy-free intervals of 180 days, more patients treated with LM responded and had numerically longer median progression-free survival.<br /><br />The analysis also compared safety outcomes between LM and OST. Outpatient visits for therapy per person-year of follow-up were lower with LM, indicating a lower treatment burden. Additionally, the rates of grade 3 thrombocytopenia and anemia were lower with LM compared to OST.<br /><br />In conclusion, this real-world analysis showed similar effectiveness outcomes between lurbinectedin monotherapy and other second-line treatments in SCLC patients. There was a suggestion of better outcomes with LM in platinum-sensitive patients. Furthermore, patients treated with LM had lower rates of grade 3 adverse events and fewer outpatient visits, suggesting a better tolerability profile.

Keywords

real-world effectiveness

safety

lurbinectedin

second-line treatments

small cell lung cancer

SCLC

monotherapy

metastatic SCLC

retrospective cohort analysis

chemotherapy-free intervals